I20. Preinfarction syndrome
Conditions
Interventions
Intervention 1: Control: Tab Placebo four times per day for two weeks from admission day. Intervention 2: Intervention: Tab Curcumin 500 mg four times per day for two weeks from addmission date.
Treatment - Drugs
Control: Tab Placebo four times per day for two weeks from admission day
Intervention: Tab Curcumin 500 mg four times per day for two weeks from addmission date
Sponsors
Mashad University of Medical Sciences, Pharmaceutical Research Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age>18; diagnosis of unstable angina with clinic and para clinic finding. Exclusion criteria: Renal and hepatic failure; infectious diseases; NSIADS and immunosuppresion drugs consumption; curcumin sensitivity; pregnancy and feeding; malignancy; chronic inflammatory disease; cardiac arrhythmia; malabsorption syndromes
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of atrial and ventricular arrhythmia. Timepoint: Between first day to 30th day post unstable angina. Method of measurement: ECG-heart exam. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in myeloperoxidase serum concentration. Timepoint: in day 0,5,10,15 post unstable angina. Method of measurement: laboratory.;Changes in matrix metaloproteinase serum concentration. Timepoint: in day 0,5,10,15 post unstable angina. Method of measurement: laboratory.;Changes in IL-18 serum concentration. Timepoint: in day 0,5,10,15 post unstable angina. Method of measurement: laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Salari
Mashad University Of Medical Sciences
Outcome results
None listed